- Real-life ruxolitinib experience in intermediate-risk myelofibrosis
-
Arikan F, Toptas T, Atagunduz IK, Ercan T, Oruc O, Yilmaz F, Tuglular T
- KMID: 2524092
- Blood Res.
- 2021 Dec;56(4):322-331.
- doi: 10.5045/br.2021.2021101
Background In this retrospective cohort of patients with primary, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis, 57 patients with MF who received ruxolitinib for MF-related symptoms or symptomatic splenomegaly were evaluated. Methods The median... -
- CITED
-
- Close
- SHARE
-
- Close
